This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Røder, M. E. Articles by Kahn, S. E. Search for Related Content PubMed PubMed Citation Articles by Røder, M. E. Articles by Kahn, S. E.

Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus¹

Divisions of Metabolism, Endocrinology, and Nutrition and Gerontology and Geriatric Medicine (R.S.S.), Department of Medicine, Veterans Affairs Puget Sound Health Care System, Harborview Medical Center (R.S.S.), and University of Washington, Seattle, Washington 98108

Address all correspondence and requests for reprints to: Michael E. Røder, M.D., Rigshospitalet, Department of Nephrology and Endocrinology P, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. E-mail address: mroder{at}login.dknet.dk

An increased proportion of fasting proinsulin (PI) relative to immunoreactive insulin (IRI; increased PI/IRI) occurs in noninsulin-dependent diabetes mellitus (NIDDM). To determine whether the magnitude of the increase in PI/IRI is an indicator of the degree of reduced B cell secretory capacity, we measured fasting plasma glucose, PI, IRI, and PI/IRI and related them to maximal B cell secretory capacity (AIRmax) in 9 subjects with NIDDM [age, 61 ± 3 yr; body mass index (BMI), 27.5 ± 1.3 kg/m²; duration of NIDDM, 10.8 ± 1.8 yr; mean ± SEM] and in 10 healthy subjects matched for age and BMI (age, 61 ± 6 yr; BMI, 27.9 ± 1.5 kg/m²). AIRmax was quantified as the incremental insulin response to iv arginine at maximal glycemic potentiation (plasma glucose >25 mmol/L).

Mean fasting plasma glucose was 13.7 ± 1.4 mmol/L (range, 7.5–18.3 mmol/L) in NIDDM subjects and 5.0 ± 0.1 mmol/L in the controls. Fasting PI was higher in NIDDM (33.1 ± 5.2) than in controls (9.4 ± 2.5 pmol/L; P < 0.01), but IRI levels were similar (93.4 ± 10.9 vs. 82.8 ± 23.4 pmol/L; P = NS). The PI/IRI ratio was significantly elevated in NIDDM compared to control subjects (35.9 ± 4.1% vs. 12.8 ± 0.8%; P < 0.01). After elevation of the glucose level to 30.3 ± 0.4 mmol/L (NIDDM) and 30.3 ± 0.5 mmol/L (controls), AIRmax was quantified as 622 ± 71 pmol/L in NIDDM and 1997 ± 315 pmol/L in controls, (P < 0.001). The PI/IRI ratio correlated inversely with AIRmax in the NIDDM patients (r = -0.76; P < 0.01).

We conclude that the magnitude of the elevation in fasting PI/IRI is related to the reduction in AIRmax. Thus, the fasting PI/IRI ratio appears to be a marker of the degree of reduced AIRmax in NIDDM.

This article has been cited by other articles:

				M. R. Rickels, R. Mueller, J. F. Markmann, and A. Naji Effect of Glucagon-Like Peptide-1 on {beta}- and {alpha}-Cell Function in Isolated Islet and Whole Pancreas Transplant Recipients J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 181 - 189. [Abstract] [Full Text] [PDF]

				A. Festa, K. Williams, A. J.G. Hanley, and S. M. Haffner {beta}-Cell Dysfunction in Subjects With Impaired Glucose Tolerance and Early Type 2 Diabetes: Comparison of Surrogate Markers With First-Phase Insulin Secretion From an Intravenous Glucose Tolerance Test Diabetes, June 1, 2008; 57(6): 1638 - 1644. [Abstract] [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio {beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191. [Abstract] [Full Text] [PDF]

				L. S. Cozma, S. D. Luzio, G. J. Dunseath, P. M. Underwood, and D. R. Owens {beta}-Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients Diabetes Care, May 1, 2005; 28(5): 1001 - 1007. [Abstract] [Full Text] [PDF]

				S. A. Smith, L. E. Porter, N. Biswas, and M. I. Freed Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6048 - 6053. [Abstract] [Full Text] [PDF]

				M. E. Roder and S. E. Kahn Suppression of Beta-Cell Secretion by Somatostatin Does Not Fully Reverse the Disproportionate Proinsulinemia of Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S22 - S25. [Abstract] [Full Text] [PDF]

				N. Stefan, M. Stumvoll, H.-U. Haring, and A. Fritsche Adiponectin in Youth: Response to Bacha et al. Diabetes Care, June 1, 2004; 27(6): 1519 - 1520. [Full Text]

				K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]

				A. Pfutzner, T. Kunt, C. Hohberg, A. Mondok, S. Pahler, T. Konrad, G. Lubben, and T. Forst Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes Diabetes Care, March 1, 2004; 27(3): 682 - 687. [Abstract] [Full Text] [PDF]

				R. J. F. Loos, P. T. Katzmarzyk, D. C. Rao, T. Rice, A. S. Leon, J. S. Skinner, J. H. Wilmore, T. Rankinen, and C. Bouchard Genome-Wide Linkage Scan for the Metabolic Syndrome in the HERITAGE Family Study J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5935 - 5943. [Abstract] [Full Text] [PDF]

				M. Maliqueo, I. Atwater, R. Lahsen, F. Perez-Bravo, B. Angel, and T. Sir-Petermann Proinsulin serum concentrations in women with polycystic ovary syndrome: a marker of {beta}-cell dysfunction? Hum. Reprod., December 1, 2003; 18(12): 2683 - 2688. [Abstract] [Full Text] [PDF]

				D. Chin, S. E. Oberfield, M. E. Silfen, D. J. McMahon, A. M. Manibo, D. Accili, and L. S. Levine Proinsulin in Girls: Relationship to Obesity, Hyperinsulinemia, and Puberty J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4673 - 4677. [Abstract] [Full Text] [PDF]

				G. Viberti, S. E. Kahn, D. A. Greene, W. H. Herman, B. Zinman, R. R. Holman, S. M. Haffner, D. Levy, J. M. Lachin, R. A. Berry, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes Diabetes Care, October 1, 2002; 25(10): 1737 - 1743. [Abstract] [Full Text] [PDF]

				A. J.G. Hanley, G. McKeown-Eyssen, S. B. Harris, R. A. Hegele, T. M.S. Wolever, J. Kwan, and B. Zinman Association of Parity With Risk of Type 2 Diabetes and Related Metabolic Disorders Diabetes Care, April 1, 2002; 25(4): 690 - 695. [Abstract] [Full Text] [PDF]

				A. Fritsche, A. Madaus, N. Stefan, O. Tschritter, E. Maerker, A. Teigeler, H. Haring, and M. Stumvoll Relationships Among Age, Proinsulin Conversion, and {beta}-Cell Function in Nondiabetic Humans Diabetes, February 1, 2002; 51(90001): S234 - 239. [Abstract] [Full Text] [PDF]

				S. E. Kahn, B. Montgomery, W. Howell, M. Ligueros-Saylan, C.-H. Hsu, D. Devineni, J. F. McLeod, A. Horowitz, and J. E. Foley Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5824 - 5829. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				C. Couillard, J.-P. Despres, B. Lamarche, J. Bergeron, J. Gagnon, A. S. Leon, D. C. Rao, J. S. Skinner, J. H. Wilmore, and C. Bouchard Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides : Evidence From Men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1226 - 1232. [Abstract] [Full Text] [PDF]

				M. E. Røder, R. S. Schwartz, R. L. Prigeon, and S. E. Kahn Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2275 - 2280. [Abstract] [Full Text]

				C. Couillard, J. Gagnon, J. Bergeron, A. S. Leon, D. C. Rao, J. S. Skinner, J. H. Wilmore, J.-P. Després, and C. Bouchard Contribution of Body Fatness and Adipose Tissue Distribution to the Age Variation in Plasma Steroid Hormone Concentrations in Men: The HERITAGE Family Study J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1026 - 1031. [Abstract] [Full Text]

				H. Larsson and B. Ahrén Relative Hyperproinsulinemia as a Sign of Islet Dysfunction in Women with Impaired Glucose Tolerance J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2068 - 2074. [Abstract] [Full Text]

				K. Hostens, Z. Ling, C. Van Schravendijk, and D. Pipeleers Prolonged Exposure of Human {beta}-Cells to High Glucose Increases Their Release of Proinsulin during Acute Stimulation with Glucose or Arginine J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1386 - 1390. [Abstract] [Full Text]

				Y. Hong, T. Rice, J. Gagnon, J.-P. Després, A. Nadeau, L. Pérusse, C. Bouchard, A. S. Leon, J. S. Skinner, J. H. Wilmore, et al. Familial Clustering of Insulin and Abdominal Visceral Fat: The HERITAGE Family Study J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4239 - 4245. [Abstract] [Full Text]